logo

For the Inventor, By the Inventor

Wuppertal, Germany

Ingo Haller

This inventor holds 35 USPTO granted patents, primarily in Antimicrobial Agents. Top assignee: Bayer Aktiengesellschaft. Active years: 1980-1998.

USPTO Granted Patents = 35

% Patents Active = 100.0

Average Co-Inventor Count = 5.9

ph-index = 10

Forward Citations = 339(Granted Patents)


Location History:

  • Wuppertal-Elberfeld, DE (1991)
  • Wuppertal, DE (1980 - 1998)

Company Filing History:

goldMedal35 out of 12,223 
 
Bayer Aktiengesellschaft
 patents

Years Active: 1980-1998

Loading Chart...
Areas of Expertise:
Antimicrobial Agents
Quinolone Derivatives
Naphthyridone
Beta-Lactamase Inhibitors
Antibacterial
Carbacephem Antibiotics
Imidazolyl Compounds
Azole Compounds
Medicinal Use
Stable Oxpenem
Hydroxypropyl-Triazole
35 patents (USPTO):Explore Patents
1. 5723627 - Preparation of 7-(3-amino- and (1998-03-03),
2. 5648493 - Preparation of 7-(3-amino- and (1997-07-15),
3. 5607942 - 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid (1997-03-04),
4. 5464796 - 7-isoindolinyl-quinolone-carboxylic acid derivatives (1995-11-07),
5. 5453422 - Quinolone- and naphthyridone carboxylic acid derivatives, process for (1995-09-26),
6. 5416096 - 7-(1-pyrrolidinyl)-3-quinolone carboxylic acid derivatives as (1995-05-16),
7. 5284855 - 7-(2,7-diazabicyclo[3.3.0]octyl)-3-quinolone-and-naphthyridonecarboxylic (1994-02-08),
8. 5284842 - Quinolone- and naphthridone carboxylic acid derivatives, process for (1994-02-08),
9. 5252734 - Antibacterial 5-alkylquinolonecarboxylic acids (1993-10-12),
10. 5202337 - 7-(2,7-diazabicyclo[3.3.0]octyl)-3-quinoline- and (1993-04-13),
11. 5190955 - Antibacterial (1993-03-02),
12. 5173484 - Quinolone- and naphthyridone carboxylic acid derivatives, process for (1992-12-22),
13. 5171854 - Substituted vinylcephalosporins (1992-12-15),
14. 5140033 - Antibacterial 5-alkylquinolonecarboxylic acids (1992-08-18),
15. 5108747 - Stable oxpenem-3-carboxylic acids as beta-lactamase inhibitors (1992-04-28),

Title: Ingo Haller: A Pioneer in Antibacterial Compound Innovation

Introduction

Ingo Haller, a prominent inventor based in Wuppertal, Germany, has made significant contributions to the field of medicinal chemistry with a focus on antibacterial compounds. With an impressive portfolio of 35 patents, Haller stands out as a leading figure at Bayer Aktiengesellschaft, where he continues to innovate and drive advancements in pharmaceutical technologies.

Latest Patents

Among Haller's most recent patents are groundbreaking processes for the preparation of antibacterial compounds. Notably, his work involves the condensation of an oxo compound with an amino compound to produce novel compounds. The intricate process includes several steps, such as reacting this compound with additional chemical entities, ultimately leading to the synthesis of effective antibacterial agents. This innovation reflects Haller's commitment to tackling challenges in antibiotic resistance and developing new solutions for healthcare.

Career Highlights

Ingo Haller's career at Bayer Aktiengesellschaft showcases his dedication to pharmaceutical research and development. His 35 patents highlight a consistent pattern of creativity and scientific rigor. Haller's efforts have contributed to advancements in the field, enabling the development of new and effective antibacterial treatments that address the needs of modern medicine.

Collaborations

Haller has collaborated with esteemed colleagues, including Karl G Metzger and Rainer Endermann. These partnerships have fostered an environment of innovation, allowing for the sharing of ideas and expertise that enrich the research process. Together, they have worked on significant projects that push the boundaries of what is possible in pharmaceutical development.

Conclusion

Ingo Haller continues to be a driving force in the world of antibacterial compound research. His numerous patents represent not only his individual achievements but also the collaborative spirit that characterizes Bayer Aktiengesellschaft. As the fight against antibiotic-resistant bacteria intensifies, Haller's contributions will undoubtedly play a vital role in shaping the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…